Methods for predicting pancreatic cancer treatment response

Patent metadata

Field	Value
Publication number	US-10760135-B2
Application number	US-201616068772-A
Country	US
Kind code	B2
Filing date	Jan 13, 2016
Priority date	Jan 13, 2016
Publication date	Sep 1, 2020
Grant date	Sep 1, 2020

Abstract

The present invention relates to methods for predicting pancreatic cancer treatment response.

First claim

The invention claimed is:

1. A method for chemosensitization of advanced pancreatic cancer in a subject in need thereof comprising the steps of:
a) determining whether a subject afflicted with advanced pancreatic cancer will be a responder to a gene therapy and gemcitabine combination treatment by
i) measuring the expression level of at least one biomarker selected from A2MG, K2C1, APOA1, EXOC2, TRFE, CO5, A16L2, FBLN3, VTNC, IGHG4, FIBG, AACT, HRG, KING1, FETUA, PLMN, THRB, KLBK1, APOH, FHR5, M3K19, CLUS, PROS, C4BP4, FIBB, miR-378, miR-145, miR-150, miR-185, miR-21, miR-484, miR-625, miR-122, miR-320, miR-335, miR-365 and miR-342-3p in a blood sample obtained from said subject before the treatment,
ii) comparing the expression level measured in step i) with a corresponding reference value derived from subjects who are non-responders to the treatment; and
iii) determining that the subject is a responder when
the expression level of one or more of A2MG, K2C1, APOA1, EXOC2, TRFE, CO5, A16L2, FBLN3, VTNC, miR-378, miR-145, miR-150, miR-185, miR-21, miR-484, miR-625, miR-122, miR-320, miR-335, miR-365 and miR-342-3p is higher than the reference value; and/or
the expression level of one or more of IGHG4, FIBG, AACT, HRG, KING1, FETUA, PLMN, THRB, KLBK1, APOH, FHR5, M3K19, CLUS, PROS, C4BP4, and FIBB is lower than the reference value; and

b) administering the gene therapy and gemcitabine combination treatment to said subject determined to be a responder, thereby chemosensitizing the subject.

2. The method of claim 1 , wherein a plurality of the biomarkers are measured in step i).

Assignees

• Inst Nat Sante Rech Med
• Univ Toulouse 3 Paul Sabatier
• Ct Hospitalier Universitaire Toulouse

Inventors

• Cordelier Pierre
• Buscail Louis
• Lopez Frédéric

Classifications

• G01N33/57525

  of the liver or pancreas · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q2600/178

  miRNA, siRNA or ncRNA · CPC title